Markets:

Overview

News

Currencies

International

Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

74.54 -0.60 (-0.80%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

49 50 Next >

DexCom (DXCM) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

Revenue hit $1.31 billion with strong international growth and margin expansion.

Via The Motley Fool

Topics Earnings

DexCom Q2 Earnings Call Highlights ↗

July 30, 2026

DexCom (NASDAQ:DXCM) reported second-quarter 2026 revenue growth of 13% from a year earlier, supported by continued demand for continuous glucose monitoring systems, expanding reimbursement access and...

Via MarketBeat

Topics Earnings

Which S&P500 stocks are moving after the closing bell on Thursday? ↗

July 30, 2026

Via Chartmill

Dexcom (NASDAQ:DXCM) Beats Q2 Earnings Estimates, Raises Profitability Guidance ↗

July 30, 2026

Via Chartmill

DEXCOM INC (NASDAQ:DXCM) Screens as a Strong Growth Stock with Favorable Technical Setup ↗

July 11, 2026

Via Chartmill

DexCom (NASDAQ:DXCM): An Affordable Growth Pick With Strong Momentum and Financial Health ↗

July 06, 2026

Via Chartmill

DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics ↗

June 08, 2026

Via Chartmill

DexCom’s (NASDAQ:DXCM) Q2 CY2026 Sales Beat Estimates

July 30, 2026

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q2 CY2026, with sales up 13.1% year on year to $1.31 billion. The compa...

Via StockStory

Topics Earnings

Dexcom Reports Second Quarter 2026 Financial Results

July 30, 2026

From DexCom, Inc.

Via Business Wire

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗

July 29, 2026

They may profit from the rapidly growing GLP-1 market in very different ways.

Via The Motley Fool

DexCom Earnings: What To Look For From DXCM

July 28, 2026

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Thursday after the bell. Here’s what to look for. DexCom beat analysts’ revenue ex...

Via StockStory

Topics Artificial Intelligence

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

July 23, 2026

From Kaskela Law LLC

Via Business Wire

Dexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot Program

July 22, 2026

From DexCom, Inc.

Via Business Wire

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

July 21, 2026

EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END

Via FinancialNewsMedia

2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid

July 21, 2026

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

Via StockStory

Explore the top gainers and losers within the S&P500 index in today's session. ↗

July 16, 2026

Via Chartmill

Exploring the top movers within the S&P500 index during today's session. ↗

July 16, 2026

Via Chartmill

1 Mid-Cap Stock to Target This Week and 2 We Find Risky

July 14, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man...

Via StockStory

Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time

July 09, 2026

From DexCom, Inc.

Via Business Wire

Patient Monitoring Stocks Q1 Results: Benchmarking DexCom (NASDAQ:DXCM)

July 02, 2026

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including DexCom (NASDAQ:DXCM) a...

Via StockStory

Topics Artificial Intelligence

2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Turn Down

July 02, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

3 Nasdaq 100 Stocks with Promising Prospects

July 01, 2026

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a ...

Via StockStory

Dexcom Further Advances Vision of Glucose Biosensing for All

June 23, 2026

From DexCom, Inc.

Via Business Wire

Should You Buy Abbott Labs Stock Hand Over Fist Before July 16? ↗

June 20, 2026

July earnings matter, but long-term growth matters more.

Via The Motley Fool

3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend ↗

June 20, 2026

With GLP-1 usage continuing to rise, a group of unlikely beneficiaries is emerging; stocks in the broader health care sector and even in retail could stand out.

Via MarketBeat

Topics ETFs

3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound ↗

June 18, 2026

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

Via MarketBeat

1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky

June 16, 2026

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...

Via StockStory

3 Reasons Investors Love DexCom (DXCM)

June 11, 2026

DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six months. At the same time, the S&P 500...

Via StockStory

Topics Stocks

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

June 10, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Via StockStory

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

June 06, 2026

From DexCom, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.